NCT02677207View on ClinicalTrials.gov

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

July 31, 2017

Conditions
Depression
Interventions
DRUG

JNJ-39393406

JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

DRUG

Placebo

JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

Trial Locations (4)

MD2011

Clinical Psychiatric Hospital, Codru

Unknown

S.C. Stefi-Dent Srl, Botoșani

Hospital of Psychiatry and Neurology, Brasov

"Spit. Clinic de Urgenta Militar Dr. Stefan Odobleja", Craiova

All Listed Sponsors
collaborator

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

lead

Tangent Data

OTHER

NCT02677207 - The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive | Biotech Hunter | Biotech Hunter